Evonik Industries AG (EVK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Evonik Industries AG (Evonik) is a company engaged in the development and production of specialty chemicals. The company's main activities include providing advanced technologies, custom solutions, and infrastructure services. Evonik's major products encompass high-performance polymers, crosslinkers, hydrogen peroxide, silicas, and additives for animal nutrition, and customized solutions like additives for coatings, adhesives, and pharmaceutical ingredients. The company serves a diverse range of industries including automotive, electronics, cosmetics, pharmaceuticals, and construction, offering products for applications such as coatings, lubricants, and medical devices. Evonik operates through a network of sites located in Germany, Slovakia, the USA, China, Singapore, Belgium, Austria, and Japan, targeting global markets. Evonik is headquartered in Essen, North Rhine-Westphalia, Germany.
Evonik Industries AG Key Recent Developments
Jun 10, 2026: More Cost-Efficient Green Hydrogen: Evonik Launches Pilot Plant for High-Performance Membrane
May 26, 2026: Evonik Partners With University of Guanajuato to Advance Sustainable Mining Chemistry
May 12, 2026: AKROS Energy Inaugurates Pilot Plant for Salt-Based Hydrogen Storage
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Section 1 - About the Company
Grunenthal GmbH - Key Facts
Grunenthal GmbH - Key Employees
Grunenthal GmbH - Key Employee Biographies
Grunenthal GmbH - Major Products and Services
Grunenthal GmbH - History
Grunenthal GmbH - Company Statement
Grunenthal GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 - Company Analysis
Company Overview
Grunenthal GmbH - Business Description
Geographical Segment: Asia/Africa/Australia
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of Europe
Performance
Geographical Segment: USA & Canada
Performance
R&D Overview
Grunenthal GmbH - SWOT Analysis
SWOT Analysis - Overview
Grunenthal GmbH - Strengths
Grunenthal GmbH - Weaknesses
Grunenthal GmbH - Opportunities
Grunenthal GmbH - Threats
Grunenthal GmbH - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Grunenthal GmbH, Recent Deals Summary
Section 4 - Company’s Recent Developments
Mar 27, 2026: Grünenthal Achieves Strong Financial Results in 2025 Through Strategic Growth and Diversification
Mar 05, 2026: Grünenthal Licenses Exclusive South Korean Rights to Qutenza to BCWorld Pharm
Feb 24, 2026: Grünenthal Licenses Exclusive Australian Rights for Qutenza to Clinect
Feb 18, 2026: Grünenthal's NaV 1.8 Inhibitor Enters Clinical Development
Feb 06, 2026: Apotex and Grünenthal sign deal for Nebido Canadian distribution
Mar 27, 2025: Grunenthal : 2024 Financial Results
Jan 09, 2025: Grunenthal Appoints Prof. Dr. Uli Brödl as Chief Scientific Officer
Section 5 - Appendix
Methodology
About the Analyst
Contact the Publisher
Disclaimer
List of Tables
Grunenthal GmbH, Key Facts
Grunenthal GmbH, Key Employees
Grunenthal GmbH, Key Employee Biographies
Grunenthal GmbH, Major Products and Services
Grunenthal GmbH, History
Grunenthal GmbH, Subsidiaries
Grunenthal GmbH, Key Competitors
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Grunenthal GmbH, Recent Deals Summary
List of Figures
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026
This product is a company SWOT Analysis. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a company SWOT Analysis. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a company SWOT Analysis. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF.
The sample excerpt is provided to help you make an informed purchasing decision. It is not intended to serve as free content or replace a full report. To ensure the sample aligns with your specific needs, our team will contact you to better understand your requirements.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net
This report can be tailored to focus on a specific country, region, continent, or provide global coverage. Please indicate your regions of interest and share any additional questions you may have. Our team strives to respond to all inquiries within the same business day.
An error occurred while sending the message. Should this issue persist, email us at help@researchandmarkets.net